SCI & TECH● LOW1h ago · Oct 25, 2026, 10:02 PM
Roche lung cancer drug extends survival by nearly six months in late-stage trial
Seeking Alpha Tech · global
A lung cancer drug developed by Roche has demonstrated the ability to extend patient survival by nearly six months in a late-stage clinical trial. This represents a notable development in medical research.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Sci & Tech
SCI & TECH1h agoWhy cloud computing pioneer Wang Jian thinks space is the next AI frontierSouth China Morning PostSCI & TECH2h agoMusk warns of AI lending crunch after SpaceX closes $40B GPU financingSeeking Alpha TechSCI & TECH3h agoXencor reports promising kidney cancer drug results, plans late-stage trialSeeking Alpha TechSCI & TECH3h agoCBD COP17: Nigeria, six others each win $50,000 grant for biodiversity projectsPremium Times